Tag: Marc Dunoyer
AstraZeneca, Cellectis join forces to boost cell, gene therapy innovations
AstraZeneca announced a strategic collaboration and investment agreement with Cellectis, a leader in clinical-stage biotechnology. This partnership, valued initially at $105 million, signifies a substantial ... Read More
Alexion’s Soliris approved for paediatric myasthenia gravis treatment in EU
Soliris (eculizumab), the first and only targeted therapy approved for the treatment of paediatric patients with refractory generalised myasthenia gravis (gMG), from Alexion, AstraZeneca Rare ... Read More
AstraZeneca’s Alexion to boost rare disease commitment with Pfizer’s gene therapy programs
Alexion, a subdivision of AstraZeneca focusing on rare diseases, has announced its definitive purchase and licensing agreement for a portfolio of preclinical gene therapy programmes ... Read More
Alexion to acquire genetic medicine company LogicBio Therapeutics
Alexion, AstraZeneca Rare Disease has agreed to acquire LogicBio Therapeutics, an American clinical-stage genetic medicine company in a deal worth $68 million. As per the ... Read More